Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7589490 | 0.92 | ESR1 (0.47) | ESR1ESR2 | |
| SCHEMBL7061202 | 0.88 | ESR1 (0.33) | ESR1ESR2 | |
| SCHEMBL5857193 | 0.85 | ESR1 (0.44) | ESR1ESR2 | |
| SCHEMBL7815677 | 0.78 | ESR1 (0.42) | ESR1ESR2 | |
| SCHEMBL5851908 | 0.75 | ESR1 (0.54) | ESR1ESR2 | |
| SCHEMBL5851970 | 0.72 | ESR1 (0.61) | ESR1 | |
| SCHEMBL5075157 | 0.72 | ESR1 (0.60) | ESR1 | |
| SCHEMBL5851880 | 0.72 | ESR1 (0.60) | ESR1 | |
| SCHEMBL243923 | 0.71 | ESR1 (0.54) | ESR1ESR2 | |
| SCHEMBL5855041 | 0.70 | APP (0.30) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074819-B2 | Benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-05-27 | — | — | US | disclosed |
| US-6645951-B1 | Antiestrogens for treating breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | NR5A1, SHBG, ESR2 | ESR1 12/4885ESR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.